These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11573858)

  • 1. Mediators of chronic heart failure: how drugs work.
    Terpening CM
    Ann Pharmacother; 2001 Sep; 35(9):1066-74. PubMed ID: 11573858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure.
    Metra M; Nodari S; D'Aloia A; Madureri A; Rosselli F; Bontempi L; Zanini R; Dei Cas L
    Eur Heart J; 1998 Feb; 19 Suppl B():B25-35. PubMed ID: 9519349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surrogate end points in heart failure.
    Lee CR; Adams KF; Patterson JH
    Ann Pharmacother; 2002 Mar; 36(3):479-88. PubMed ID: 11895063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
    Trindade PT; Rouleau JL
    Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurohumoral blockade in CHF management.
    Willenbrock R; Philipp S; Mitrovic V; Dietz R
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1 Suppl 1():24-30. PubMed ID: 11967792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of heart failure.
    Schrier RW; Abdallah JG; Weinberger HH; Abraham WT
    Kidney Int; 2000 Apr; 57(4):1418-25. PubMed ID: 10760077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents.
    Bristow MR
    Am J Cardiol; 1993 Mar; 71(9):12C-22C. PubMed ID: 8096671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurohormones and heart failure: the importance of aldosterone.
    Odedra K; Ferro A
    Int J Clin Pract; 2006 Jul; 60(7):835-46. PubMed ID: 16846401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms.
    Lee CS; Tkacs NC
    AACN Adv Crit Care; 2008; 19(4):364-85; quiz 386-7. PubMed ID: 18981739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart failure and angiotensin converting enzyme inhibition: problems and perspectives.
    Simko F; Simko J
    Physiol Res; 1999; 48(1):1-8. PubMed ID: 10470860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical use of markers of neurohormonal activation in heart failure].
    Roig Minguell E
    Rev Esp Cardiol; 2004 Apr; 57(4):347-56. PubMed ID: 15104989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurohormones and heart failure.
    Mendzef SD; Slovinski JR
    Nurs Clin North Am; 2004 Dec; 39(4):845-61. PubMed ID: 15561165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopressin receptor antagonists. Therapeutic potential in the management of acute and chronic heart failure.
    Russell SD; DeWald T
    Am J Cardiovasc Drugs; 2003; 3(1):13-20. PubMed ID: 14727942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for the survival benefit of neurohormonal antagonists in the management of geriatric congestive heart failure.
    Firdaus M; Bukhari N
    J Okla State Med Assoc; 2003 Mar; 96(3):133-9. PubMed ID: 12688226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
    Sigurdsson A
    Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
    Cohn JN; Anand IS; Latini R; Masson S; Chiang YT; Glazer R;
    Circulation; 2003 Sep; 108(11):1306-9. PubMed ID: 12939207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
    Pölzl G; Gouya G; Hügel H; Frick M; Ulmer H; Pachinger O
    Wien Klin Wochenschr; 2002 Oct; 114(19-20):833-9. PubMed ID: 12503474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?
    Emdin M; Fatini C; Mirizzi G; Poletti R; Borrelli C; Prontera C; Latini R; Passino C; Clerico A; Vergaro G
    Clin Chim Acta; 2015 Mar; 443():85-93. PubMed ID: 25445411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
    Yan RT; White M; Yan AT; Yusuf S; Rouleau JL; Maggioni AP; Hall C; Latini R; Afzal R; Floras J; Masson S; McKelvie RS;
    Am J Cardiol; 2005 Sep; 96(5):698-704. PubMed ID: 16125499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conclusions on the management of heart failure.
    Swedberg K
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S34-6. PubMed ID: 15526241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.